694-68-8

Basic information

• Product Name: MTH-GLYCINE
• Synonyms: MTH-GLYCINE;MTH-Glycine Methylthiohydantoin-glycine;methylthiohydantoin;3-Methyl-2-thioxo-4-iMidazolidinone;4-IMidazolidinone, 3-Methyl-2-thioxo-;3-methyl-2-sulfanylideneimidazolidin-4-one
• CAS NO: 694-68-8
• Molecular Formula: C₄H₆N₂OS
• Molecular Weight: 130.17
• Mol File: 694-68-8.mol
• Article Data: 15

Chemical Properties

• Melting Point: 214-215 °C(Solv: water (7732-18-5))
• Boiling Point: 176.8°C at 760 mmHg
• Flash Point: 60.7°C
• Appearance: /Solid
• Density: 1.4g/cm³
• Vapor Pressure: 1.07mmHg at 25°C
• Refractive Index: 1.634
• Storage Temp.: 2-8°C
• PKA: 9.47±0.20(Predicted)
• CAS DataBase Reference: MTH-GLYCINE(CAS DataBase Reference)
• NIST Chemistry Reference: MTH-GLYCINE(694-68-8)
• EPA Substance Registry System: MTH-GLYCINE(694-68-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 694-68-8(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 73, p. 3749, 1951 DOI: 10.1021/ja01152a056

InChI:InChI=1/C4H6N2OS/c1-6-3(7)2-5-4(6)8/h2H2,1H3,(H,5,8)

Upstream product

• 586966-06-5 N²-methyl-thiazole-2,5-diyldiamine 
• 7647-01-0 hydrogenchloride 
• 64143-06-2 1-acetyl-3-methyl-2-thiohydantoin 
• 131543-46-9 Glyoxal 
• 598-52-7 1-(methyl)-thiourea 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 556-61-6 methyl thioisocyanate 
• 79-04-9 chloroacetyl chloride 
• 104892-40-2 (3-Methyl-thioureido)-acetic acid ethyl ester 
• 56-40-6 glycine 
• 51675-49-1 N-methyl-N'-(carboxymethyl)thiocarbamide 

Downstream Products

• 88568-71-2 5-(2-chloro-benzylidene)-3-methyl-2-thioxo-imidazolidin-4-one 
• 95474-20-7 (5Z)-5-benzylidene-3-methyl-2-thioxoimidazolidin-4-one 
• 79851-71-1 5-(4-chlorobenzylidene)-3-methyl-2-thiohydantoin 
• 79851-69-7 3-Methyl-2-thioxo-5-[1-p-tolyl-meth-(E)-ylidene]-imidazolidin-4-one 
• 1621252-49-0 (5Z)-3-methyl-5-[4-(2,2':6',2''-terpyridin-4'-yl)benzylidene]-2-thioxoimidazolidin-4-one 
• 1416577-04-2 (5Z)-5(4-methoxybenzylidene)-3-methyl-2-thioxoimidazolidin-4-one 

Relevant articles and documents

DUAL-INHIBITORS OF CELLULAR NECROPTOSIS AND FERROPTOSIS FOR USE IN THE TREATMENT OF ORGAN TRANSPLANT PATIENTS

The invention relates to chemical compounds for use as a medicament in the prevention of organ transplant rejection and/or transplant organ damage. In embodiments of the invention, the compound inhibits and/or reduces ferroptosis and necroptosis of cells of the transplanted organ. In further embodiments, the patient is at risk of transplant rejection and/or is at risk of or shows signs of ischemia-reperfusion injury and/or necroinflammation.

NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES

Provided are novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases. Specifically, provided are the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs, prepa

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds

Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce α-ketoglutaric acid (α-KG) to d-2-hydroxyglutaric acid (D2HG). The resulting high concentration of D2HG inhibits many α-KG-dependent dioxygenases, including histone demethylases, to cause broad histone hypermethylation. These aberrant epigenetic changes are responsible for the initiation of these cancers. We report the synthesis, structure-activity relationships, enzyme kinetics, and binding thermodynamics of a novel series of 2-thiohydantoin and related compounds, among which several compounds are potent inhibitors of mutant IDH1 with Ki as low as 420 nM. X-ray crystal structures of IDH1(R132H) in complex with two inhibitors are reported, showing their inhibitor-protein interactions. These compounds can decrease the cellular concentration of D2HG, reduce the levels of histone methylation, and suppress the proliferation of stem-like cancer cells in BT142 glioma with IDH1 R132H mutation.